Core Viewpoint - U.S. stock futures are up, with Dow futures increasing by over 300 points, while shares of Cassava Sciences fell sharply after disappointing Phase 3 study results for Simufilam in Alzheimer's patients [1]. Company Summaries - Cassava Sciences, Inc. experienced a significant decline in share price, dropping 85.6% to 3.82inpre−markettradingfollowingtheannouncementthatSimufilamdidnotshowasignificantreductionincognitivedeclinecomparedtoplacebointheReThink−ALZPhase3study[2][1].−CentessaPharmaceuticalsPLCsawitssharestumble1215.00 in pre-market trading after reporting a quarterly loss of 0.37pershare[4].−BiohavenLtd.sharesfell1140.60 after the treatment arm of the RESILIENT SMA study did not statistically separate from the placebo group at Week 48 [4]. - ZIM Integrated Shipping Services Ltd. shares dipped 6.9% to 22.15despitereportingbetter−than−expectedthird−quarterfinancialresultsandraisingFY24adjustedEBITandEBITDAguidance[4].−i3Verticals,Inc.sharesdeclined6.622.11 after posting disappointing quarterly results [4]. - ChromaDex Corporation shares fell 5.9% to 7.00inpre−markettrading[4].−FitellCorporationsharesdeclined4.924.00 after gaining around 6% on the previous trading day [4]. - Logility Supply Chain Solutions, Inc. shares fell 4.4% to 9.31afterreportingworse−than−expectedsecond−quarterrevenueresultsandissuingFY25revenueguidancebelowestimates[4].−KingsoftCloudHoldingsLimitedsharesfell4.36.90 after a significant jump of around 25% on the previous trading day, despite reporting a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), which was up 16.0% year-on-year and exceeded analyst expectations [4].